Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma After Radical Surgery With Donafenib in Combination With Envafolimab: a Prospective, Multicentre, Single-arm Phase II Clinical Study

NCT06498622 is registered in ClinicalTrials.gov with Anhui Provincial Hospital as lead sponsor.

NCT NCT06498622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06498622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma After Radical Surgery With Donafenib in Combination With Envafolimab: a Prospective, Multicentre, Single-arm Phase II Clinical Study
Lead sponsor
Anhui Provincial Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
July 20, 2024
Completion date
May 20, 2027
Enrollment
45 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma